Lenalidomid Wh

Lenalidomide, the active ingredient in Lenalidomid Wh, is an immunomodulatory drug presented as an oral formulation for oral use. It is employed in the treatment of certain blood cancers, including multiple myeloma, myelodysplastic syndromes and mantle cell lymphoma, in adult patients who have relapsed or refractory disease.

GNH USA supplies Lenalidomid Wh as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenalidomid Wh is an immunomodulatory antineoplastic agent indicated for specific hematologic malignancies.

Multiple myeloma: used in combination regimens to improve progression‑free survival in relapsed or refractory patients. Myelodysplastic syndromes: indicated for patients with del(5q) cytogenetic abnormality to reduce transfusion dependence. Mantle cell lymphoma: employed as part of therapy for relapsed or refractory disease to achieve disease control.

Lenalidomid Wh may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue - Neutropenia - Thrombocytopenia - Diarrhea - Rash - Constipation

Serious or Rare Side Effects: - Venous thromboembolism - Secondary primary malignancies - Severe neutropenia or infection - Hepatic failure or elevated transaminases - Severe cutaneous reactions (e.g., Stevens‑Johnson syndrome) - Tumor lysis syndrome

When prescribing Lenalidomid Wh, clinicians should observe several safety measures.

Pregnancy: contraindicated (Category X) – avoid use in pregnant women. Thrombosis risk: assess patient history and consider prophylactic anticoagulation. Hematologic monitoring: perform regular complete blood counts to detect cytopenias. Renal impairment: adjust dosing and monitor renal function closely. Drug interactions: avoid concomitant use with strong CYP3A4 inducers. Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Lenalidomid Wh can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce lenalidomide exposure. - Anticoagulants such as warfarin: increased risk of bleeding. - Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (e.g., aspirin): monitor for bleeding tendencies. - Other immunomodulatory agents: may enhance immunosuppressive effects. - Hepatotoxic drugs: monitor liver enzymes for additive toxicity.